38585-74-9

Basic information

• Product Name: 5-Hydroxymethylthiazole
• Synonyms: CHEMBRDG-BB 4050354;5-HYDROXYMETHYLTHIAZOLE;1,3-THIAZOL-5-YLMETHANOL;THIAZOLE-5-METHANOL;THIAZOL-5-YL-METHANOL;RARECHEM AL BD 1261;5-THIAZOLE METHANOL;5-hyrdoxymethyl thiazole
• CAS NO: 38585-74-9
• Molecular Formula: C₄H₅NOS
• Molecular Weight: 115.15
• EINECS: 414-780-9
• Product Categories: blocks;Thiazoles;Heterocycles;Heterocyclic Compounds;API;Sulfur & Selenium Compounds;Ritonavir
• Mol File: 38585-74-9.mol

Chemical Properties

• Boiling Point: 95-96°C 0,02mm
• Flash Point: 104.1 °C
• Appearance: Pale-yellow oil
• Density: 1.32
• Vapor Pressure: 0.0128mmHg at 25°C
• Refractive Index: 1.5670 to 1.5710
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform, Methanol
• PKA: 13.61±0.10(Predicted)
• CAS DataBase Reference: 5-Hydroxymethylthiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxymethylthiazole(38585-74-9)
• EPA Substance Registry System: 5-Hydroxymethylthiazole(38585-74-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-52/53-41-40
• Safety Statements: 26-36/37/39-61-39-36-22
• Hazardous Substances Data: 38585-74-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Hydroxymethylthiazole is used as a synthetic building block for the development of various organic compounds. Its presence in the molecule allows for the creation of a wide range of chemical products, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Hydroxymethylthiazole is used as an intermediate in the synthesis of therapeutically relevant compounds. Its unique structure contributes to the development of new drugs with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Industry:
5-Hydroxymethylthiazole is also utilized in the agrochemical industry for the synthesis of active ingredients in pesticides and other crop protection products. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases.
Used in Specialty Chemicals:
In the specialty chemicals sector, 5-Hydroxymethylthiazole is employed in the production of various chemicals with specific applications, such as additives, dyes, and coatings. Its versatility in organic synthesis makes it a valuable component in the development of these specialized products.

InChI:InChI=1/C4H5NOS/c6-2-4-1-5-3-7-4/h1,3,6H,2H2

Upstream product

• 32955-22-9 ethyl thiazole-5-carboxylate 
• 170232-68-5 (2,4-dibromo-1,3-thiazol-5-yl)methanol 
• 170232-69-6 2,4-dichloro-5-(hydroxymethyl)thiazole 
• 1003-32-3 thiazole-5-carboxaldehyde 
• 14527-44-7 methyl thiazole-5-carboxylate 
• 145015-15-2 2-chloro-5-(hydroxymethyl)thiazole 
• 1167055-75-5 methyl 2-oxo 5-thiazol carboxylate 
• 75-45-6 Chlorodifluoromethane 
• 262444-15-5 (4-bromo-1,3-thiazol-5-yl)methanol 
• 67000-01-5 methyltertbutyl ether 

Downstream Products

• 45438-77-5 5-thiazolylmethyl chloride 
• 144163-97-3 ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate 
• 656236-17-8 {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid thiazol-5-ylmethyl ester 
• 1003-32-3 thiazole-5-carboxaldehyde 
• 181040-44-8 2-Fluoro-4-(thiazol-5-ylmethoxy)benzonitrile 
• 1126776-84-8 4-[3,5-dimethyl-1-(1,3-thiazol-5-ylmethyl)-1H-pyrazol-4-yl]benzonitrile 
• 1227853-57-7 C₁₁H₁₅NS₂ 
• 167998-61-0 5-(bromomethyl)thiazole 
• 1360628-83-6 3-fluoro-4-[7-methoxy-3-methyl-2-oxo-8-(thiazol-5-ylmethoxy)-2,3-dihydroimidazo-[4,5-c]quinolin-1-yl]benzonitrile 
• 933751-05-4 N-(thiazol-5-ylmethyl)methylamine 
• 920479-55-6 C₇H₁₀N₂S 
• 1169870-28-3 C₃₆H₅₃N₇O₅S₂ 
• 1247119-33-0 N-((1R,4R)-4-amino-5-phenyl-1-benzylpentyl)carbamic acid 5-thiazolylmethyl ester hydrochloride 

Relevant articles and documents

Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120

In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses. The X-ray structure of a similar compound, NBD-14010, confirmed the binding mode of the newly designed compounds. The in vitro ADMET profiles of these compounds are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clinical trials. The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compounds with the potential to be moved to the early preclinical development.

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.

Rapid and efficient synthesis of stable isotope labeled [ 13C4, D4]-5-(hydroxymethyl)thiazole: Versatile building block for biologically interesting compounds

5-(Hydroxymethyl)thiazole is a versatile building block for many biologically active compounds. A rapid and efficient four- step synthesis of its stable isotope labeled counterpart with four 13C and four deuterium atoms in 32% total yield is reported. Condensation of [13C 2]-chloro acetic acid with [13C]-thiourea gave [ 13C3]-2,4-thiazolidinedione. Reaction of [ 13C3]-2,4-thiazolidinedione with phosphorus oxybromide and [13C, D]-DMF (Me2N13CDO) produced [ 13C4 D]-2,4-dibromo- thiazole-5-carboxaldehyde. The resultant aldehyde was then reduced by sodium borodeuteride to [ 13C4, D2]-(2,4-dibromo- thiazol-5-yl)-methanol. Catalytic deuteration of [13C4, D2]-(2,4- dibromo-thiazol-5-yl)-methanol by palladium black with deuterium gas at 1 atm pressure and room temperature produced completely de-brominated [ 13C4, D4]-5-(hydro- xymethyl)thiazole. De-bromination of the 2,4-dibromothiazole by the catalysis of palladium black provides a simple and convenient synthetic method for the stable isotope labeled and potentially radioactive isotope labeled thiazole compounds. Copyright

Synthesis and properties of NLO chromophores with fine-tuned gradient electronic structures

A novel series of heterocycle-based NLO chromophores based on different combinations of auxiliary donor (i.e., benzene, thiophene and pyrrole) and auxiliary acceptor (i.e., thiazole with different regiochemistries) were designed and synthesized. Due to the different electron-rich and poor nature of the auxiliary donors and acceptors, respectively, the resulting NLO chromophores have systematically varied ground-state electronic structures, as evidenced by the 1H NMR, CV and UV-vis investigations. The nonlinear optical properties of the resulting NLO chromophores were studied by UV-vis spectroscopy, Hyper-Rayleigh scattering (HRS), and semi-empirical computations. All the chromophores have very large molecular hyperpolarizabilities (β1000 nm) in the range of 704-1500 × 10-30 esu (or β0, 318-768 × 10-30 esu), which showed a great sensitivity to the gradient electronic structures. Upon increasing the electron density from benzene to thiophene and to pyrrole, substantial increases in β0 were observed; significantly larger β0 values were also observed for NLO chromophores based on "matched" thiazole (C2 is connected to the acceptor) than those based on "un-matched" thiazole (C5 is connected to the acceptor). TGA investigations showed good thermal stability for the resulting NLO chromophores. However, with the increase of electron density of the auxiliary donor, a decrease in thermal and photochemical stability was observed. It is interesting to note that NLO chromophores based on triarylamine as the donor and thiazole as the auxiliary acceptor exhibited not only high thermal stability but also very large β0 values.

Chemical Compounds

This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

BROADSPECTRUM SUBSTITUTED BENZISOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS

The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs esters and metabolites thereof.It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.

Retroviral protease inhibiting compounds

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors

PCT No. PCT/US94/09139 Sec. 371 Date Jan. 24, 1996 Sec. 102(e) Date Jan. 24, 1996 PCT Filed Aug. 23, 1994 PCT Pub. No. WO95/06030 PCT Pub. Date Mar. 2, 1995The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A compound of the formula: STR1 is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.